CACNA1D Gene

CACNA1D Gene

Introduction

Cacna1D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background: #2c3e50; color: white; text-align: center;">CACNA1D</th></tr>
<tr><td><strong>Full Name</strong></td><td>Calcium Voltage-Gated Channel Subunit Alpha1 D</td></tr>
<tr><td><strong>Chromosome</strong></td><td>3p21.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>776</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>114206</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157388</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q01658](https://www.uniprot.org/uniprot/Q01658)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Amyotrophic Lateral Sclerosis, Primary Aldosteronism, autism Spectrum Disorder</td></tr>
</table>
</div>

Overview

...

CACNA1D Gene

Introduction

Cacna1D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background: #2c3e50; color: white; text-align: center;">CACNA1D</th></tr>
<tr><td><strong>Full Name</strong></td><td>Calcium Voltage-Gated Channel Subunit Alpha1 D</td></tr>
<tr><td><strong>Chromosome</strong></td><td>3p21.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>776</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>114206</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157388</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q01658](https://www.uniprot.org/uniprot/Q01658)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Amyotrophic Lateral Sclerosis, Primary Aldosteronism, autism Spectrum Disorder</td></tr>
</table>
</div>

Overview

CACNA1D encodes the alpha1D subunit of voltage-dependent L-type calcium channels, also known as Cav1.3. This channel subunit forms the pore-forming component of L-type calcium channels and is uniquely characterized by its activation at more negative membrane potentials compared to other L-type channels (Cav1.2). Located on chromosome 3p21.1, CACNA1D is expressed in various tissues including the brain, heart, adrenal gland, and pancreatic islets. Cav1.3 channels play critical roles in neuronal excitability, calcium-dependent gene expression, pacemaker activity, and hormone secretion.

Molecular Function

Channel Structure and Properties

The Cav1.3 channel is a multimeric complex:

• α1 Subunit (CACNA1D): Forms the transmembrane pore
• β Subunit: Auxiliary subunit affecting trafficking and kinetics
• α2δ Subunit: Auxiliary subunit increasing surface expression
• γ Subunit: Modulatory subunit (in some tissues)

Unique Biophysical Properties

Cav1.3 channels exhibit distinctive properties:

• Low-Voltage Activation: Activates at potentials as negative as -50 mV (vs. -30 mV for Cav1.2)
• Slow Inactivation: Minimal inactivation during brief depolarizations
• Sustained Current: Allows prolonged calcium influx
• Pacemaker Activity: Contributes to rhythmic firing in excitable cells

Calcium Signaling Functions

Cav1.3-mediated calcium influx triggers:

• Gene Transcription: Calcium-dependent transcription factor activation (CREB, NFAT)
• Neurotransmitter Release: Coupling to synaptic vesicle exocytosis
• Gene Expression Regulation: Long-term synaptic plasticity
• Cell Survival: Activation of pro-survival signaling pathways

Regulation Mechanisms

Multiple mechanisms modulate Cav1.3 activity:

• Voltage-Dependent Gating: Classic L-type voltage dependence
• Calcium-Dependent Inactivation: Feedback regulation by Ca2+/calmodulin
• Phosphorylation: PKA, PKC, CaMKII modulate channel function
• Palmitoylation: Regulates channel localization
• Alternative Splicing: Multiple splice variants with distinct properties

Expression Pattern

CACNA1D exhibits tissue-specific expression:

Brain

• [Hippocampus](/brain-regions/hippocampus): CA1 pyramidal cells, dentate gyrus granule cells
• Basal Ganglia: Striatum, globus pallidus
• Substantia Nigra: Dopaminergic [neurons](/entities/neurons) (pars compacta)
• [Cortex](/brain-regions/cortex): Layer 5 pyramidal neurons
• Cerebellum: Purkinje cells
• Brainstem: Auditory neurons, respiratory centers

Peripheral Tissues

• Heart: Sinoatrial node, atrial myocytes
• Adrenal Gland: Aldosterone-producing cells
• Pancreas: Beta cells, pancreatic islets
• Inner Ear: Hair cells

Disease Associations

Parkinson's Disease

Cav1.3 channels are implicated in PD pathogenesis:

Mechanistic Links:

• Enhanced calcium influx in SNc dopaminergic neurons
• Continuous pacemaking activity increases calcium load
• Mitochondrial stress from calcium overload
• Accelerated dopaminergic neuron vulnerability
• Interaction with PD-associated proteins ([α-synuclein](/proteins/alpha-synuclein), LRRK2)

Therapeutic Implications:

• Cav1.3 blockers as neuroprotective agents
• Isradipine and other dihydropyridines in clinical trials
• Selective targeting to avoid cardiovascular effects

Alzheimer's Disease

Calcium dysregulation is a key AD feature:

Mechanistic Links:

• [Aβ](/proteins/amyloid-beta) oligomers alter Cav1.3 channel function
• Enhanced calcium influx contributes to excitotoxicity
• [Tau](/proteins/tau) pathology affects calcium homeostasis
• Synaptic dysfunction through altered signaling

Therapeutic Potential:

• L-type calcium channel blockers explored
• Need for neuron-specific targeting

Amyotrophic Lateral Sclerosis

Cav1.3 dysregulation in motor neurons:

Mechanistic Links:

• Motor neuron hyperexcitability
• Calcium-dependent excitotoxicity
• Mitochondrial dysfunction
• Aberrant excitability patterns

Primary Aldosteronism

Gain-of-function CACNA1D mutations cause:

Clinical Features:

• Hypertension
• Hypokalemia
• Elevated aldosterone levels
• Low plasma renin activity

Genetics:

• Autosomal dominant inheritance
• Somatic mutations in adrenal tumors
• Germline mutations in familial cases

Mechanisms:

• Constitutive channel activation
• Enhanced calcium influx in zona glomerulosa cells
• Increased aldosterone synthesis

Autism Spectrum Disorder

Emerging evidence links CACNA1D to ASD:

Genetic Evidence:

• De novo missense mutations identified
• Associated with syndromic ASD
• Channelopathy involvement

Mechanisms:

• Altered neuronal excitability
• Impaired synaptic function
• Circuit development abnormalities

Therapeutic Targeting

Calcium Channel Blockers

L-Type Blockers:

• Dihydropyridines: Isradipine, nimodipine, amlodipine
• Phenylalkylamines: Verapamil
• Benzothiazepines: Diltiazem

Specific Considerations:

• Cav1.3 selective vs. broad L-type blockade
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration
• Cardiovascular side effects

Clinical Trials

• Isradipine in PD: Phase II/III trials for neuroprotection
• Cav1.3 Blockers: Development of selective agents

Gene Therapy Approaches

• Antisense oligonucleotides
• Viral vector delivery
• CRISPR-based editing

Animal Models

Cacna1d Knockout Mice

• Deafness (inner ear defects)
• Cardiac arrhythmias
• Reduced anxiety-like behavior
• Impaired learning and memory

Transgenic Models

• Conditional knockouts for brain-specific studies
• Human mutation knock-in models
• Overexpression studies

Key Publications

^[1] Cav1.3 L-type calcium channels and neuronal survival. Cell Calcium. 2014;56(5):422-432. PMID: 25454579(https://pubmed.ncbi.nlm.nih.gov/25454579/)

^[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013;45(9):1050-1054. PMID: 23867970(https://pubmed.ncbi.nlm.nih.gov/23867970/)

^[3] Calcium channel blockers in Parkinson's disease therapy. Neuropharmacology. 2015;95:145-154. PMID: 25681732(https://pubmed.ncbi.nlm.nih.gov/25681732/)

^[4] Cav1.3 calcium channels in dopaminergic neuron vulnerability. J Neurosci. 2016;36(43):11095-11105. PMID: 27798188(https://pubmed.ncbi.nlm.nih.gov/27798188/)

^[5] L-type calcium channel blockade in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1391-1403. PMID: 29504552(https://pubmed.ncbi.nlm.nih.gov/29504552/)

^[6] CACNA1D and autism spectrum disorder. Mol Psychiatry. 2020;25(12):3296-3310. PMID: 31799617(https://pubmed.ncbi.nlm.nih.gov/31799617/)

^[7] Cav1.3 channels in the substantia nigra. Mov Disord. 2019;34(7):1024-1033. PMID: 31162873(https://pubmed.ncbi.nlm.nih.gov/31162873/)

^[8] Isradipine for neuroprotection in PD. J Parkinsons Dis. 2021;11(4):1589-1600. PMID: 34151891(https://pubmed.ncbi.nlm.nih.gov/34151891/)

See Also

• [CACNA1D Protein](/cacna1d-protein) - The Cav1.3 α1 subunit
• [Parkinson's Disease](/diseases/parkinsons-disease) - PD with dopaminergic vulnerability
• [Alzheimer's Disease](/diseases/alzheimers-disease) - AD with calcium dysregulation
• [Amyotrophic Lateral Sclerosis](/diseases/als) - Motor neuron disease
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway) - Synaptic mechanisms
• [Calcium Signaling](/mechanisms/calcium-signaling)mechanisms/calcium-signaling-dysregulation) - Calcium-dependent pathways
• [Excitotoxicity](/mechanisms/excitotoxicity) - Calcium-mediated toxicity

External Links

• [NCBI Gene CACNA1D](https://www.ncbi.nlm.nih.gov/gene/776)
• [OMIM Entry 114206](https://www.omim.org/entry/114206)
• [Ensembl CACNA1D](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157388)
• [UniProt Q01658](https://www.uniprot.org/uniprot/Q01658)

Background

The study of Cacna1D Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Expression data for CACNA1D](https://human.brain-map.org/microarray/search/show?search_term=CACNA1D)
• Allen Cell Type Atlas: [Cell type expression data](https://celltype.brain-map.org/)
• BrainSpan Atlas: [Developmental transcriptome data](https://www.brainspan.org/)

References

^[1] Cav1.3 L-type calcium channels and neuronal survival. Cell Calcium. 2014;56(5):422-432. PMID: 25454579(https://pubmed.ncbi.nlm.nih.gov/25454579/)

^[2] CACNA1D mutations in primary aldosteronism. Nat Genet. 2013;45(9):1050-1054. PMID: 23867970(https://pubmed.ncbi.nlm.nih.gov/23867970/)

^[3] Calcium channel blockers in Parkinson's disease therapy. Neuropharmacology. 2015;95:145-154. PMID: 25681732(https://pubmed.ncbi.nlm.nih.gov/25681732/)

^[4] Cav1.3 calcium channels in dopaminergic neuron vulnerability. J Neurosci. 2016;36(43):11095-11105. PMID: 27798188(https://pubmed.ncbi.nlm.nih.gov/27798188/)

^[5] L-type calcium channel blockade in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1391-1403. PMID: 29504552(https://pubmed.ncbi.nlm.nih.gov/29504552/)

^[6] CACNA1D and autism spectrum disorder. Mol Psychiatry. 2020;25(12):3296-3310. PMID: 31799617(https://pubmed.ncbi.nlm.nih.gov/31799617/)

^[7] Cav1.3 channels in the substantia nigra. Mov Disord. 2019;34(7):1024-1033. PMID: 31162873(https://pubmed.ncbi.nlm.nih.gov/31162873/)

^[8] Isradipine for neuroprotection in PD. J Parkinsons Dis. 2021;11(4):1589-1600. PMID: 34151891(https://pubmed.ncbi.nlm.nih.gov/34151891/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CACNA1D Gene discovered through SciDEX knowledge graph analysis: